NCT06481189View on ClinicalTrials.gov

A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

March 17, 2023

Study Completion Date

May 26, 2023

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

GNR-086

The test drug GNR-086 was administered as a subcutaneous injection at a single dose of 150 mg.

BIOLOGICAL

Ilaris®

The reference drug Ilaris® was administered as a subcutaneous injection at a single dose of 150 mg.

Trial Locations (2)

117556

"State budgetary healthcare institution of the city of Moscow City Clinic No. 2 of the Moscow Health Department", Moscow

127473

"Federal State Budgetary Educational Institution of Higher Education Moscow State Medical and Dental University named after A.I. Evdokimov of the Ministry of Health of the Russian Federation", Moscow

All Listed Sponsors
lead

AO GENERIUM

INDUSTRY